Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SSY Group ( (HK:2005) ) has provided an announcement.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Indobufen Tablets, a type 3 chemical drug. This development marks a significant step in the company’s product offerings, particularly in the treatment and prevention of ischemic cardiovascular and cerebrovascular diseases, as well as thrombosis during hemodialysis. The approval enhances SSY Group’s position in the pharmaceutical market, potentially benefiting shareholders and investors by expanding its product portfolio and market reach.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a company involved in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is known for its work in the treatment of cardiovascular and cerebrovascular diseases, as well as thrombosis prevention.
Average Trading Volume: 14,180,600
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.36B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.